Your position:Home > News >

A novel stable and non-solvate crystal form II on Apremilast and processes for the preparation thereof


 We are planning to transfer the right of patent application on the crystal form II of Apremilast to companies who are interested in. Pls contact with us if you need more information.

We found a novel  crystal form on Apremilast and named it as crystal form II,which is completely different from  crystalline A, B, C, D, E, F and G reported by Celgene. Its DSC spectrum  exhibits a single peak about 150℃and its TG spectrum show a mass loss of less than about  0.5% when heated from about 25 to 150℃.
Our study confirmed that the crystal form II is the most thermodynamically stable anhydrous form of apremilast than the crystal form A, B, C, D, E, F and G because the crystal form A-G could  be totally converted to crystal form II in some condition without dissolving. There are almost no difference in solubility between II and B in all kinds of solvents. Recently we performed comparison experiment on rats, and the absorption of those 2 crystallines are very similar, except stronger activity of Crystalline II in female rats. Moreover, the absorption of those 2 crystal are very similar on dog. 
  Now we resubmitted the relate patent application on the Crystal form II of Apremilast in China, the application number is CN201510101009. Next, we will apply for PCT patent ASAP.
Patents on Apremilast:


Address: West 5th Floor, Building D, No. 1999, Duhui Rd., Minhang district, Shanghai, PR China,
Zip Code 201108
Contact Mr.Huang
Mr. Luo
Tel 86-21-54091930,54091296
Cel 86-21-13816330796
Fax 86-21-54091296

Declaration:Patented and controlled compounds are provided for research only

links: Private Policy| freeonli| FDA| EMEA|

Copyright © 2010 Utopharm Shanghai Co., Ltd. All Rights Reserved